Tower Research Capital (TRC)’s BioLineRX BLRX Stock Holding History
Bought
Maintained
Sold
Other funds holding BLRX
Tower Research Capital (TRC)'s BLRX Position: Q3 2026 in Review
Tower Research Capital (TRC) opened a new position in BioLineRX (BLRX) in Q3 2026: 181 shares worth $425. The stake represents ﹤0.01% of the portfolio and ranks #5575 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BLRX as recently as Q3 2025.
Tower Research Capital (TRC) first reported a position in BLRX in Q3 2013 and has held it in 7 quarters since. The position peaked at $28K in Q4 2013. 17 funds tracked by Wall St. Rank hold BLRX as of Q3 2026.
- Tower Research Capital (TRC) held 181 shares of BioLineRX worth $425 as of Q3 2026.
- BioLineRX was a new Tower Research Capital (TRC) position in Q3 2026.
- BioLineRX made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5575 holding.
- Tower Research Capital (TRC) first reported a position in BioLineRX in Q3 2013 and has held it in 7 quarters since.
- Tower Research Capital (TRC)'s BioLineRX position peaked at $28K in Q4 2013.
- 17 funds tracked by Wall St. Rank held BioLineRX as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.